

A PATENT IS SET TO BE GRANTED IN AUSTRALIA FOR INHALATION OF PHARMACEUTICALS

Emplicure AB (publ) today announces that a patent is set to be granted by the Australian Patent Office for inhalation of pharmaceuticals.

The Australian Patent Office has confirmed its intention to grant the patent application for inhalation of pharmaceuticals, application No 2017227070. This means the review and examination phase has passed and all terms are fulfilled. The patent is expected to be granted within the next months, and then into 2038.

"This patent to be confirms the strength in our patent strategy to protect commercially important markets. It allows us to push forward towards outlicensing and co-development agreements for new and inhaled pharmaceuticals, developed on our proprietary bioceramic technology platforms. We have recently received the equivalent information for the U.S. and Japan." says Torbjörn W. Larsson, CEO of Emplicure.

For more information, please contact:

Torbjörn W. Larsson

CEO

Phone: +46 (0)70 747 65 99

Email: twl@emplicure.com

Erik Magnusson

CFO, Investor Relations

Phone: +46 (0)708 565 245

Email: erik.magnusson@emplicure.com

Adviser

Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via ca@mangold.se

This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons above, on April 1, 2022 at 08:45 CET.



Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subsidiary, Amplicon AB develops consumer products, with tobacco-free nicotine as the first product. Read more at www.emplicure.com